重组人干扰素α1b联合布地奈德治疗毛细支气管炎患儿疗效观察

Effect of recombinant human interferon alpha 1b combined with budesonide in children with bronchiolitis

目的毛细支气管炎是小儿常见下呼吸道感染性疾病,多由呼吸道合胞病毒感染引起。本研究探讨重组人干扰素α1b联合布地奈德治疗毛细支气管炎患儿疗效。方法选取2017-08-01-2018-08-01我院收治的毛细支气管炎患儿104例,根据组间性别、病程、年龄均衡原则分为观察组和对照组,各52例。对照组雾化吸入布地奈德,观察组增加重组人干扰素α1b治疗,治疗7d后,统计2组临床疗效、症状消失时间及治疗前后C反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)水平。结果观察组总有效率为96.15%,高于对照组的82.69%,χ^2=4.981,P=0.026。观察组喘憋消失时间为(3.50±1.42)d,短于对照组的(4.41±2.86)d,t=2.055,P=0.042;观察组咳嗽消失时间为(5.49±2.58)d,短于对照组的(7.42±3.56)d,t=3.166,P=0.002;观察组肺部哮鸣音消失时间为(5.61±1.20)d,短于对照组的(6.64±2.49)d,t=2.687,P=0.008;观察组三凹征消失时间为(4.36±1.48)d,短于对照组的(5.23±1.32)d,t=3.164,P=0.002;观察组发热消失时间为(2.10±1.01)d,短于对照组的(4.02±1.43)d,t=7.908,P<0.001。治疗7d后,观察组PCT水平为(0.25±0.11)μg/L,低于对照组的(0.55±0.15)μg/L,t=11.630,P<0.001;观察组CRP水平为(3.20±0.74)mg/L,低于对照组的(4.52±0.86)mg/L,t=8.390,P<0.001。结论重组人干扰素α1b联合吸入用布地奈德治疗毛细支气管炎患儿疗效确切,可有效缩短症状消失时间,减轻炎症反应。

OBJECTIVE Bronchiolitis is a common lower respiratory tract infectious disease in children,which is mostly caused by respiratory syncytial virus infection.This study aims to investigate the effect of recombinant human interferon alpha 1 bcombined with budesonide in the treatment of children with bronchiolitis.METHODS Totally 104 children with bronchiolitis admitted to our hospital from August 1,2017 to August 1,2018 were divided into observation group and control group according to the balance principle of gender,course of disease and age,52 cases in each group.The control group was inhaled budesonide by atomization,while the observation group was added recombinant human interferon alpha 1 b.After 7 days of treatment,the clinical efficacy,the time of symptom disappearance and the level of C-reactive protein(CRP)and procalcitonin(PCT)before and after treatment were counted.RESULTS The total effective rate of the observation group was 96.15%,which was higher than that of the control group(82.69%),χ^2=4.981,P=0.026.The disappearance time of asthma in the observation group was(3.50±1.42)d,which was shorter than that of the control group(4.41±2.86)d,t=2.055,P=0.042.The disappearance time of cough in the observation group was(5.49±2.58)d,which was shorter than that of the control group(7.42±3.56)d,t=3.166,P=0.002.The disappearance time of the wheezing sound of the lungs in the observation group was(5.61±1.20)d,which was shorter than that of the control group(6.64±2.49)d,t=2.687,P=0.008.The disappearance time of the three concave signs in the observation group was(4.36±1.48)d,which was shorter than that of the control group(5.23±1.32)d,t=3.164,P=0.002.The disappearance time of fever in the observation group was(2.10±1.01)d,which was shorter than that of the control group(4.02±1.43)d,t=7.908,P<0.001.After seven days treatment,the PCT level of the observation group was(0.25±0.11)μg/L,which was lower than that of the control group(0.55±0.15)μg/L,t=11.630,P<0.001.The CRP level of the observation group was(3.20±0.74)mg/L,which was lower than that of the control group(4.52±0.86)mg/L,t=8.390,P<0.001.CONCLUSION Recombinant human interferonα1 bcombined with budesonide is effective for the treatment of children with bronchiolitis,which can shorten the time for disappearance of symptoms and reduce inflammation.